Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:11231031rdf:typepubmed:Citationlld:pubmed
pubmed-article:11231031lifeskim:mentionsumls-concept:C0026769lld:lifeskim
pubmed-article:11231031lifeskim:mentionsumls-concept:C0033147lld:lifeskim
pubmed-article:11231031lifeskim:mentionsumls-concept:C0026336lld:lifeskim
pubmed-article:11231031lifeskim:mentionsumls-concept:C0011304lld:lifeskim
pubmed-article:11231031lifeskim:mentionsumls-concept:C1883709lld:lifeskim
pubmed-article:11231031pubmed:issue1lld:pubmed
pubmed-article:11231031pubmed:dateCreated2001-3-20lld:pubmed
pubmed-article:11231031pubmed:abstractTextThe demyelinating plaque is the paradigmatic lesion of multiple sclerosis (MS), but only recently attention has been given to axonal damage and to its role in the pathophysiology of disease. Albeit the possible relevance of axonal loss in MS and its experimental models, the amount and timing of axonal sufferance has been addressed only in experimental autoimmune encephalomyelitis (EAE) of rodents. In this report we observed that, in the marmoset model of EAE, axonal damage occurs early during the demyelinating process as assessed by immunoreactivity for amyloid precursor protein (APP) and non-phosphorylated neurofilaments (SMI-32 positive) detected mostly in early active lesions compared to late active and normal appearing white matter. The rare occurrence of morphological features of axonal transection, such as APP or SMI-32 positive spheroids and swellings, as well as an increase of neurofilament density in the demyelinated axons without accumulation of electron dense organelles or osmiophilic bodies, at electron microscopy, suggests that early axonal damage may be, at least in part, a reversible process. These findings are of relevance for the development of therapies, which can protect axons and enhance their function and survival.lld:pubmed
pubmed-article:11231031pubmed:languageenglld:pubmed
pubmed-article:11231031pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11231031pubmed:citationSubsetIMlld:pubmed
pubmed-article:11231031pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11231031pubmed:statusMEDLINElld:pubmed
pubmed-article:11231031pubmed:monthFeblld:pubmed
pubmed-article:11231031pubmed:issn0022-510Xlld:pubmed
pubmed-article:11231031pubmed:authorpubmed-author:HartBBlld:pubmed
pubmed-article:11231031pubmed:authorpubmed-author:MassacesiLLlld:pubmed
pubmed-article:11231031pubmed:authorpubmed-author:BrouRRlld:pubmed
pubmed-article:11231031pubmed:authorpubmed-author:UccelliAAlld:pubmed
pubmed-article:11231031pubmed:authorpubmed-author:CapelliOOlld:pubmed
pubmed-article:11231031pubmed:authorpubmed-author:MancardiGGlld:pubmed
pubmed-article:11231031pubmed:authorpubmed-author:BontropRRlld:pubmed
pubmed-article:11231031pubmed:authorpubmed-author:GiuntiDDlld:pubmed
pubmed-article:11231031pubmed:authorpubmed-author:Roccatagliata...lld:pubmed
pubmed-article:11231031pubmed:issnTypePrintlld:pubmed
pubmed-article:11231031pubmed:day15lld:pubmed
pubmed-article:11231031pubmed:volume184lld:pubmed
pubmed-article:11231031pubmed:ownerNLMlld:pubmed
pubmed-article:11231031pubmed:authorsCompleteYlld:pubmed
pubmed-article:11231031pubmed:pagination41-9lld:pubmed
pubmed-article:11231031pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:11231031pubmed:meshHeadingpubmed-meshheading:11231031...lld:pubmed
pubmed-article:11231031pubmed:meshHeadingpubmed-meshheading:11231031...lld:pubmed
pubmed-article:11231031pubmed:meshHeadingpubmed-meshheading:11231031...lld:pubmed
pubmed-article:11231031pubmed:meshHeadingpubmed-meshheading:11231031...lld:pubmed
pubmed-article:11231031pubmed:meshHeadingpubmed-meshheading:11231031...lld:pubmed
pubmed-article:11231031pubmed:meshHeadingpubmed-meshheading:11231031...lld:pubmed
pubmed-article:11231031pubmed:meshHeadingpubmed-meshheading:11231031...lld:pubmed
pubmed-article:11231031pubmed:meshHeadingpubmed-meshheading:11231031...lld:pubmed
pubmed-article:11231031pubmed:meshHeadingpubmed-meshheading:11231031...lld:pubmed
pubmed-article:11231031pubmed:meshHeadingpubmed-meshheading:11231031...lld:pubmed
pubmed-article:11231031pubmed:year2001lld:pubmed
pubmed-article:11231031pubmed:articleTitleDemyelination and axonal damage in a non-human primate model of multiple sclerosis.lld:pubmed
pubmed-article:11231031pubmed:affiliationDepartment of Neurological Sciences and Vision, University of Genoa, Via De Toni 5, 16132 Genoa, Italy. neurolab@cisi.unige.itlld:pubmed
pubmed-article:11231031pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:11231031pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:11231031lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:11231031lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:11231031lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:11231031lld:pubmed